| scholarly article | Q13442814 |
| P50 | author | Helio S Sader | Q63144492 |
| Ronald N Jones | Q120908182 | ||
| P2093 | author name string | Susanne Paukner | |
| Zrinka Ivezic-Schoenfeld | |||
| P2860 | cites work | Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia | Q22241905 |
| Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults | Q22242958 | ||
| Interaction of pleuromutilin derivatives with the ribosomal peptidyl transferase center | Q24542414 | ||
| Population pharmacokinetic analyses for BC-3781 using phase 2 data from patients with acute bacterial skin and skin structure infections | Q30864336 | ||
| Skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus USA300 clone | Q33686212 | ||
| Antibiotic Substances From Basidiomycetes: VIII. Pleurotus Multilus (Fr.) Sacc. and Pleurotus Passeckerianus Pilat | Q33711689 | ||
| Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections | Q35806254 | ||
| Epidemiology and etiology of community-acquired pneumonia | Q35957889 | ||
| MRSA--what is it, and how do we deal with the problem? | Q36150828 | ||
| Transition of Enterococcus faecium from commensal organism to nosocomial pathogen. | Q37628671 | ||
| The science of selecting antimicrobials for community-acquired pneumonia (CAP). | Q37855220 | ||
| The pleuromutilin drugs tiamulin and valnemulin bind to the RNA at the peptidyl transferase centre on the ribosome | Q43736215 | ||
| Methicillin-resistant Staphylococcus aureus disease in three communities | Q46426018 | ||
| Methicillin-ResistantS. aureusInfections among Patients in the Emergency Department | Q55897489 | ||
| Managing skin and soft tissue infections: expert panel recommendations on key decision points | Q79353901 | ||
| Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs) | Q83353954 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibiotic | Q12187 |
| P304 | page(s) | 4489-4495 | |
| P577 | publication date | 2013-07-08 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010. | |
| P478 | volume | 57 |
| Q33792789 | A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii |
| Q41872353 | A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism |
| Q58766556 | An antimycobacterial pleuromutilin analogue effective against dormant bacilli |
| Q38772340 | Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium |
| Q40448204 | In Vitro Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China. |
| Q34525879 | In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States |
| Q52659745 | In Vitro Activity of Lefamulin against Sexually Transmitted Bacterial Pathogens. |
| Q40052692 | In vitro activity of the novel pleuromutilin lefamulin (BC-3781) and effect of efflux pump inactivation on multidrug-resistant and extensively-drug resistant Neisseria gonorrhoeae |
| Q64072703 | In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model |
| Q64072714 | Introduction: lefamulin and pharmacokinetic/pharmacodynamic rationale to support the dose selection of lefamulin |
| Q42355223 | Mycoplasma genitalium infections: current treatment options and resistance issues |
| Q38247457 | Natural product and natural product derived drugs in clinical trials. |
| Q90327504 | Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial |
| Q64072718 | Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia |
| Q64072710 | Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing |
| Q64072706 | Pharmacokinetics/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model with Staphylococcus aureus and Streptococcus pneumoniae |
| Q37835585 | Pleuromutilins: Potent Drugs for Resistant Bugs-Mode of Action and Resistance |
| Q64072699 | Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methods |
| Q34497915 | Structural insights into species-specific features of the ribosome from the pathogen Staphylococcus aureus |
| Q40065527 | Synergistic Effect of Pleuromutilins with Other Antimicrobial Agents against Staphylococcus aureus In Vitro and in an Experimental Galleria mellonella Model |
| Q91742696 | The Continuing Threat of Methicillin-Resistant Staphylococcus aureus |
| Q39120027 | What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles |
Search more.